IRIS
MINOTTI, GIORGIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 9.118
NA - Nord America 3.366
EU - Europa 1.655
SA - Sud America 523
AF - Africa 68
OC - Oceania 34
Continente sconosciuto - Info sul continente non disponibili 1
Totale 14.765
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 6.276
US - Stati Uniti d'America 3.223
CN - Cina 1.268
HK - Hong Kong 996
IT - Italia 652
BR - Brasile 373
GB - Regno Unito 257
FR - Francia 220
VN - Vietnam 209
DE - Germania 155
IN - India 93
CZ - Repubblica Ceca 72
MX - Messico 61
NL - Olanda 58
AR - Argentina 54
CA - Canada 54
RU - Federazione Russa 42
ID - Indonesia 38
BD - Bangladesh 34
FI - Finlandia 34
AU - Australia 32
JP - Giappone 28
IQ - Iraq 25
UA - Ucraina 24
BE - Belgio 22
EC - Ecuador 22
TR - Turchia 22
ES - Italia 20
CO - Colombia 19
ZA - Sudafrica 19
PL - Polonia 18
PY - Paraguay 18
CL - Cile 15
SA - Arabia Saudita 15
MY - Malesia 14
PK - Pakistan 13
PH - Filippine 12
PE - Perù 10
JO - Giordania 9
SE - Svezia 9
TN - Tunisia 9
UZ - Uzbekistan 9
EE - Estonia 8
MA - Marocco 8
TW - Taiwan 8
AE - Emirati Arabi Uniti 7
AL - Albania 7
CR - Costa Rica 7
PT - Portogallo 7
VE - Venezuela 7
EG - Egitto 6
JM - Giamaica 6
LT - Lituania 6
MD - Moldavia 6
NP - Nepal 6
AT - Austria 5
HU - Ungheria 5
RO - Romania 5
DO - Repubblica Dominicana 4
TH - Thailandia 4
AO - Angola 3
AZ - Azerbaigian 3
BA - Bosnia-Erzegovina 3
BG - Bulgaria 3
GE - Georgia 3
HR - Croazia 3
IE - Irlanda 3
IL - Israele 3
IR - Iran 3
KW - Kuwait 3
NA - Namibia 3
UY - Uruguay 3
BO - Bolivia 2
BY - Bielorussia 2
DM - Dominica 2
DZ - Algeria 2
ET - Etiopia 2
GA - Gabon 2
KG - Kirghizistan 2
KN - Saint Kitts e Nevis 2
KZ - Kazakistan 2
LV - Lettonia 2
LY - Libia 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
OM - Oman 2
PA - Panama 2
SI - Slovenia 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
AG - Antigua e Barbuda 1
AM - Armenia 1
BF - Burkina Faso 1
BH - Bahrain 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CV - Capo Verde 1
CY - Cipro 1
DK - Danimarca 1
Totale 14.748
Salva come PNG Salva come JPEG
Città #
San Jose 1.227
Hong Kong 987
Singapore 813
Ashburn 698
Rome 546
Hefei 455
Beijing 303
Boardman 269
London 204
Lauterbourg 199
Shanghai 149
Dallas 114
Council Bluffs 72
Munich 71
Ho Chi Minh City 70
Los Angeles 65
San Francisco 59
Redmond 56
Brno 54
Santa Clara 53
Amsterdam 43
Hanoi 42
São Paulo 38
Pune 37
New York 36
Mexico City 29
Toronto 28
Washington 22
Seattle 20
Brooklyn 19
Turku 19
Haiphong 18
Melbourne 17
Olomouc 17
Hasselt 16
Tokyo 16
West Jordan 16
Chicago 15
Helsinki 14
Rio de Janeiro 13
Warsaw 13
Boston 12
Frankfurt am Main 12
Guangzhou 12
Atlanta 11
Chennai 11
Manchester 11
Quito 11
Canberra 10
Orem 10
Johannesburg 9
New Delhi 9
Nuremberg 9
Phoenix 9
Riyadh 9
Amman 8
Asunción 8
Biên Hòa 8
Fortaleza 8
Hangzhou 8
Tashkent 8
Bengaluru 7
Bogotá 7
Brasília 7
Buenos Aires 7
Catania 7
Da Nang 7
Kuala Lumpur 7
Lima 7
Montreal 7
Paris 7
San José 7
Ankara 6
Baghdad 6
Belo Horizonte 6
Campinas 6
Dhaka 6
Haikou 6
Poplar 6
Curitiba 5
Formosa 5
Hanover 5
Milan 5
Moscow 5
Oklahoma City 5
Santiago 5
Shenzhen 5
Stockholm 5
Sulaymaniyah 5
Sydney 5
The Dalles 5
Tirana 5
Barletta 4
Blumenau 4
Cairo 4
Caxias do Sul 4
Changsha 4
Charlotte 4
Denver 4
Erbil 4
Totale 7.361
Salva come PNG Salva come JPEG
Nome #
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. 222
Proceedings of an International Workshop on Anthracycline Cardiotoxicity 209
An investigation into thee mechanism of citrateFE2+-dependent lipid peroxidation 208
Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker? 206
Altered iron regulatory protein activities in doxorubicin-treated cardiomyocytes : Distinct roles of reactive oxygen species and of the secondary alcohol metabolite doxorubicinol 206
Cell Biology and Toxicology: Special Issue on Cardiovascular Liability of Drugs 204
Cancer drugs and QT prolongation: weighing risk against benefit 203
Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial 203
A supposed role for superoxide dismutase in the control of tumor growth 202
Minimal sampling colistin pharmacokinetics in critically ill patients 201
Doxorubicinolone formation and efflux : A salvage pathway against epirubicin accumulation in human heart 200
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life 200
Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study. 195
The endogenous lusitropic and chronotropic agent, B-type natriuretic peptide, limits cardiac troponin release in cancer patients with an early impairment of myocardial relaxation induced by anthracyclines 194
A Special Section on Clinical Pharmacology-Editorial 193
Cardiovascular toxicity of antitumor drugs :Translating molecular mechanisms into clinical facts 192
4’- Epidoxorubicin to reexplore anthracycline degradation in cardiomyocytes 190
Acute Heart Failure 29 Years After Treatment for Childhood Cancer 189
Adriamycin dependent release of iron from human lung tumor microsomes : Biochemical mechanisms and clinical implications 188
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines 182
Cardio-oncology in clinical studies and real life 181
Anthracycline cardiotoxicity in breast cancer patients: Synergism with trastuzumab and taxanes 179
Defective taxane stimulation of epirubicinol formation in the human heart: Insights into the cardiac tolerability of epirubicin-taxane chemotherapies 177
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology 160
Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity 156
Pharmacology of cardio-oncology: chronotropic and lusitropic effects of B-type natriuretic peptide in cancer patients with early diastolic dysfunction induced by anthracycline or nonanthracycline chemotherapy 137
Anthracycline Cardiotoxicity 134
Anthracycline metabolism and toxicity in human myocardium : Comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with reduced formation and [4Fe-4S]-reactivity of its secondary alcohol metabolite 128
Anthracyclines 124
Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study 123
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival 121
Anthracycline metabolism and toxicity in human myocardyum: Comparisons between doxorubicin, epirubicin, and a novel disaccaride analogue with redeced formation and [4Fe-4S]-reactivity of its secondary alchol metabolite 120
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). 118
Anthracycline Cardiotoxicity 109
Adriamycin dependent release of iron from microsomal membranes 108
An Invitation from the Editors of Cardio-Oncology 107
Activation of heme oxygenase and consequent carbon monoxide formation inhibits the release of arginine vasopressin from rat hypothalamic explants. Molecular linkage between heme catabolism and neuroendocrine function. Mol Brain Res. 106
Anthracycline cardiotoxicity 106
All Eyes on Me, Please: Ocular Palonosetron for the Cancer Patient with Nausea and Vomiting 103
Adriamycin alcohol dependent iron mobilization : A novel mechanism of adriamycin cardiotoxicity? 103
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: Relative importance of vesicular sequestration and impaired efficiency of electron addition 102
An introduction to the metabolic determinants of anthracycline cardiotoxicity 101
Cardiotoxicity of antitumor drugs 99
CARDIAC ANTHRACYCLINE ACCUMULATION AND B-TYPE NATRIURETIC PEPTIDE TO DEFINE RISK AND PREDICTORS OF CANCER TREATMENT RELATED EARLY DIASTOLIC DYSFUNCTION 98
Cardiotoxicity of targeted cancer drugs: concerns, “The cart before the horse,” and lessons from trastuzumab 88
Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny 87
Low dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites 84
Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity 77
Anthracyclines, diastolic dysfunction and the road to heart failure in Cancer survivors: An untold story 74
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement 72
Ibrutinib and Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death 70
Isavuconazole: case report and pharmacokinetic considerations 69
Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. Oncology. 66
Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma 66
Pharmacology of Cardio-Oncology 65
Rethinking drugs from chemistry to therapeutic opportunities: Pixantrone beyond Anthracyclines. 64
Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin 62
What is cardiotoxicity? 61
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin 61
Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation: Implications for Cardiotoxicity of Anticancer Anthracyclines 60
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies 59
Further analytical, pharmacokinetic, and clinical observations on low-dose ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 59
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach 58
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox 58
Post-transcriptional control of hepatic oxidative stress respone 58
Early diagnosis of acute coronary syndrome. 58
Novel mechanisms for the inhibition of low density lipoprotein oxidation by ascorbic acid. 58
Safety and tolerability of a novel oral nutritional supplement in healthy volunteers 57
Cardiotoxicity of antitumor drugs 56
NEW TARGETED DRUGS FOR ACUTE MYELOID LEUKEMIA AND ANTIFUNGALS: PHARMACOKINETIC CHALLENGES AND OPPORTUNITIES 55
Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium 55
Vitamin E inhibits enhanced F2 isoprostane biosynthesis in type IIA hypercholesterolemia excretion 55
Nitric oxide and peroxynitrite activate the iron regulatory protein-1 of J774A.1 macrophages by direct disassembly of the Fe-S cluster of cytoplasmic aconitase 55
Platelets: the point of interconnection among cancer, inflammation and cardiovascular diseases 55
Cancer incidence and mortality in patients diagnosed with heart failure: results from an updated systematic review and meta-analysis 54
Anthracycline secondary alcohol metabolite formation in human or rabbit heart ; Biochemical aspects and pharmacological implications 54
Doxorubicin toxicity in human heart: role of C-13 metabolite, c-aconitase and iron 53
Identification, prevention and management of cardiovascular risk in chronic myeloid leukaemia patients candidate to ponatinib: an expert opinion. 53
Cardiovascular Toxicity of non cardiovascular drugs 53
Doxorubicin-Dexrazoxane from day 1 for soft-tissue sarcomas: The road to cardioprotection 53
Mechanisms and clinical course of cardiovascular toxicity of cancer treatment II. Hematology 52
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 52
Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin 52
The iron regulatory proteins: targets and modulators of free radical reactions and oxidative damage 52
Development of a tumor-specific photoactivatable doxorubicin prodrug. 52
The [Fe-S] cluster of cytoplasmic aconitase as a novel target of anthracycline cardiotoxicity 52
Predictors of early or delayed diastolic dysfunction after anthracycline-based or nonanthracycline chemotherapy: a pharmacological appraisal 52
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin treated patients 51
Pixantrone: novel mode of action and clinical readouts. 51
Factors influencing superoxide and t-BuOOH dependent lipid peroxidation of tumor microsomes 51
In vitro modelling of the structure-activity determinants of anthracycline cardiotoxicity 51
Drug-induced hepatotoxicity in cancer patients - implication for treatment 51
Doxorubicin irreversibly inactivates Iron Regulatory Proteins 1 and 2 in cardiomyocytes : Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy 51
Quo Vadis COVID? Lessons from a Focus Topic Issue of Chemotherapy 51
Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence 50
Pharmacological Foundation of Cardio-Oncology 50
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 50
Sodium–glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond 48
Doxorubicin metabolism to toxic species in human myocardium: stimulation by paclitaxel and docetaxel but not BMS 184476 or BMS 188797 48
Paradoxical inhibition of cardiac lipid peroxidation in cancer patients treated with doxorubicin. Pharmacologic and molecular reappraisal of anthracycline cardiotoxicity 48
Totale 10.244
Salva come PNG Salva come JPEG
Categoria #
all - tutte 107.390
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 107.390
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022527 0 5 0 1 0 1 2 214 7 7 7 283
2022/2023108 2 4 5 8 7 5 13 0 2 7 51 4
2023/2024776 22 87 29 55 96 329 9 29 6 24 10 80
2024/20257.426 150 67 268 29 72 168 91 32 690 586 2.541 2.732
2025/20266.107 714 289 311 693 260 348 1.881 527 504 525 55 0
Totale 14.944